The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with early ...
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
The lifetime risk of dementia after age 55 is about 42% - more than double the risk reported by earlier studies, and one that puts greater urgency on the need to mitigate addressable health problems, ...